A teutonic wave of biotech start-ups is gathering, fed by government money, new venture funds and a handful of academics. But given the cultural and managerial obstacles, it's not certain that this wave will have the energy to reach the shore.
by Roger Longman
Had Christiane Nüsslein-Volhard, PhD, been an American academic of equal stature, the answer to her question would have been simple:...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.
Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.
